William Blair Issues Negative Outlook for PRCT Earnings

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) - Equities research analysts at William Blair cut their Q1 2026 EPS estimates for PROCEPT BioRobotics in a note issued to investors on Monday, April 28th. William Blair analyst B. Vazquez now expects that the company will post earnings of ($0.32) per share for the quarter, down from their prior estimate of $0.32. The consensus estimate for PROCEPT BioRobotics' current full-year earnings is ($1.75) per share. William Blair also issued estimates for PROCEPT BioRobotics' Q3 2026 earnings at ($0.16) EPS.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.04. The company had revenue of $69.16 million during the quarter, compared to analysts' expectations of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business's quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.51) EPS.

Other analysts have also recently issued research reports about the company. Truist Financial decreased their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. Morgan Stanley decreased their price objective on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Finally, Bank of America cut their target price on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, PROCEPT BioRobotics has a consensus rating of "Moderate Buy" and an average target price of $90.00.

PROCEPT BioRobotics Trading Up 5.2 %

NASDAQ:PRCT traded up $2.77 on Wednesday, hitting $55.62. 930,808 shares of the stock were exchanged, compared to its average volume of 807,234. The stock has a fifty day moving average of $56.75 and a 200-day moving average of $73.36. The stock has a market cap of $3.08 billion, a PE ratio of -28.52 and a beta of 1.09. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics has a fifty-two week low of $47.04 and a fifty-two week high of $103.81.

Insider Activity

In other news, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,455 shares of company stock worth $368,322 over the last 90 days. Company insiders own 17.40% of the company's stock.

Institutional Investors Weigh In On PROCEPT BioRobotics

A number of hedge funds have recently bought and sold shares of PRCT. Raleigh Capital Management Inc. purchased a new position in shares of PROCEPT BioRobotics during the 4th quarter valued at approximately $32,000. Thematics Asset Management bought a new position in PROCEPT BioRobotics during the 4th quarter valued at $46,000. CWM LLC grew its holdings in PROCEPT BioRobotics by 69.5% during the 1st quarter. CWM LLC now owns 873 shares of the company's stock worth $51,000 after acquiring an additional 358 shares in the last quarter. Signaturefd LLC increased its position in shares of PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after purchasing an additional 145 shares during the last quarter. Finally, IFP Advisors Inc acquired a new stake in shares of PROCEPT BioRobotics in the 4th quarter valued at about $58,000. Institutional investors and hedge funds own 89.46% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).